Ran Jin1, Rob McConnell2, Cioffi Catherine3, Shujing Xu4, Douglas I Walker5, Nikos Stratakis6, Dean P Jones7, Gary W Miller8, Cheng Peng9, David V Conti10, Miriam B Vos11, Leda Chatzi12. 1. Department of Preventive Medicine, University of Southern California, Los Angeles, CA, USA. Electronic address: jinr@usc.edu. 2. Department of Preventive Medicine, University of Southern California, Los Angeles, CA, USA. Electronic address: rmcconne@usc.edu. 3. Nutrition and Health Sciences Program, Laney Graduate School, Emory University, Atlanta, GA, USA. Electronic address: catherine.cioffi@emory.edu. 4. Department of Preventive Medicine, University of Southern California, Los Angeles, CA, USA. Electronic address: shujingx@usc.edu. 5. Clinical Biomarkers Laboratory, Division of Pulmonary Allergy, Critical Care and Sleep Medicine, Emory University, Atlanta, GA, USA; Rollins School of Public Health, Emory University, Atlanta, GA, USA. Electronic address: douglas.walker@mssm.edu. 6. Department of Preventive Medicine, University of Southern California, Los Angeles, CA, USA. Electronic address: nstratak@usc.edu. 7. Clinical Biomarkers Laboratory, Division of Pulmonary Allergy, Critical Care and Sleep Medicine, Emory University, Atlanta, GA, USA. Electronic address: dpjones@emory.edu. 8. Rollins School of Public Health, Emory University, Atlanta, GA, USA. Electronic address: gary.miller@columbia.edu. 9. Department of Preventive Medicine, University of Southern California, Los Angeles, CA, USA. Electronic address: chengpen@usc.edu. 10. Department of Preventive Medicine, University of Southern California, Los Angeles, CA, USA. Electronic address: dconti@med.usc.edu. 11. Nutrition and Health Sciences Program, Laney Graduate School, Emory University, Atlanta, GA, USA; Children's Healthcare of Atlanta, Atlanta, GA, USA. Electronic address: mvos@emory.edu. 12. Department of Preventive Medicine, University of Southern California, Los Angeles, CA, USA. Electronic address: chatzi@usc.edu.
Abstract
BACKGROUND: Toxicant-associated steatohepatitis has been described in adults but less is known regarding the role of toxicants in liver disease of children. Perfluoroalkyl substances (PFAS) cause hepatic steatosis in rodents, but few previous studies have examined PFAS effects on severity of liver injury in children. OBJECTIVES: We aimed to examine the relationship of PFAS to histologic severity of nonalcoholic fatty liver disease (NAFLD) in children. METHODS: Seventy-four children with physician-diagnosed NAFLD were recruited from Children's Healthcare of Atlanta between 2007 and 2015. Biopsy-based liver histological features were scored for steatosis, lobular and portal inflammation, ballooning, and fibrosis. Plasma concentrations of perfluorooctanoic acid (PFOA), perfluorooctane sulfonate (PFOS) and perfluorohexane sulfonic acid (PFHxS), and untargeted plasma metabolomic profiling, were determined using liquid chromatography with high-resolution mass spectrometry. A metabolome-wide association study coupled with pathway enrichment analysis was performed to evaluate metabolic dysregulation associated with PFAS. A structural integrated analysis was applied to identify latent clusters of children with more severe form of NAFLD based on their PFAS levels and metabolite pattern. RESULTS: Patients were 7-19 years old, mostly boys (71%), Hispanic (51%), and obese (85%). The odds of having nonalcoholic steatohepatitis (NASH), compared to children with steatosis alone, was significantly increased with each interquartile range (IQR) increase of PFOS (OR: 3.32, 95% CI: 1.40-7.87) and PFHxS (OR: 4.18, 95% CI: 1.64-10.7). Each IQR increase of PFHxS was associated with increased odds for liver fibrosis (OR: 4.44, 95% CI: 1.34-14.8), lobular inflammation (OR: 2.87, 95% CI: 1.12-7.31), and higher NAFLD activity score (β coefficient 0.46; 95% CI: 0.03, 0.89). A novel integrative analysis identified a cluster of children with NASH, characterized by increased PFAS levels and altered metabolite patterns including higher plasma levels of phosphoethanolamine, tyrosine, phenylalanine, aspartate and creatine, and decreased plasma levels of betaine. CONCLUSIONS: Ηigher PFAS exposure was associated with more severe disease in children with NAFLD. PFAS may be an important toxicant contributing to NAFLD progression; however larger, longitudinal studies are warranted to confirm these findings.
BACKGROUND: Toxicant-associated steatohepatitis has been described in adults but less is known regarding the role of toxicants in liver disease of children. Perfluoroalkyl substances (PFAS) cause hepatic steatosis in rodents, but few previous studies have examined PFAS effects on severity of liver injury in children. OBJECTIVES: We aimed to examine the relationship of PFAS to histologic severity of nonalcoholic fatty liver disease (NAFLD) in children. METHODS: Seventy-four children with physician-diagnosed NAFLD were recruited from Children's Healthcare of Atlanta between 2007 and 2015. Biopsy-based liver histological features were scored for steatosis, lobular and portal inflammation, ballooning, and fibrosis. Plasma concentrations of perfluorooctanoic acid (PFOA), perfluorooctane sulfonate (PFOS) and perfluorohexane sulfonic acid (PFHxS), and untargeted plasma metabolomic profiling, were determined using liquid chromatography with high-resolution mass spectrometry. A metabolome-wide association study coupled with pathway enrichment analysis was performed to evaluate metabolic dysregulation associated with PFAS. A structural integrated analysis was applied to identify latent clusters of children with more severe form of NAFLD based on their PFAS levels and metabolite pattern. RESULTS: Patients were 7-19 years old, mostly boys (71%), Hispanic (51%), and obese (85%). The odds of having nonalcoholic steatohepatitis (NASH), compared to children with steatosis alone, was significantly increased with each interquartile range (IQR) increase of PFOS (OR: 3.32, 95% CI: 1.40-7.87) and PFHxS (OR: 4.18, 95% CI: 1.64-10.7). Each IQR increase of PFHxS was associated with increased odds for liver fibrosis (OR: 4.44, 95% CI: 1.34-14.8), lobular inflammation (OR: 2.87, 95% CI: 1.12-7.31), and higher NAFLD activity score (β coefficient 0.46; 95% CI: 0.03, 0.89). A novel integrative analysis identified a cluster of children with NASH, characterized by increased PFAS levels and altered metabolite patterns including higher plasma levels of phosphoethanolamine, tyrosine, phenylalanine, aspartate and creatine, and decreased plasma levels of betaine. CONCLUSIONS: Ηigher PFAS exposure was associated with more severe disease in children with NAFLD. PFAS may be an important toxicant contributing to NAFLD progression; however larger, longitudinal studies are warranted to confirm these findings.
Authors: Kaberi P Das; Carmen R Wood; Mimi T Lin; Anatoly A Starkov; Christopher Lau; Kendall B Wallace; J Christopher Corton; Barbara D Abbott Journal: Toxicology Date: 2016-12-31 Impact factor: 4.221
Authors: Carolyn Jonas Accardi; Douglas I Walker; Karan Uppal; Arshed A Quyyumi; Patricia Rohrbeck; Kurt D Pennell; Col Timothy M Mallon; Dean P Jones Journal: J Occup Environ Med Date: 2016-08 Impact factor: 2.162
Authors: Matthew T Martin; Richard J Brennan; Wenyue Hu; Eser Ayanoglu; Christopher Lau; Hongzu Ren; Carmen R Wood; J Christopher Corton; Robert J Kavlock; David J Dix Journal: Toxicol Sci Date: 2007-03-22 Impact factor: 4.849
Authors: Robert J Kuczmarski; Cynthia L Ogden; Shumei S Guo; Laurence M Grummer-Strawn; Katherine M Flegal; Zuguo Mei; Rong Wei; Lester R Curtin; Alex F Roche; Clifford L Johnson Journal: Vital Health Stat 11 Date: 2002-05
Authors: Quinlyn A Soltow; Frederick H Strobel; Keith G Mansfield; Lynn Wachtman; Youngja Park; Dean P Jones Journal: Metabolomics Date: 2013-03 Impact factor: 4.290
Authors: Karan Uppal; Quinlyn A Soltow; Frederick H Strobel; W Stephen Pittard; Kim M Gernert; Tianwei Yu; Dean P Jones Journal: BMC Bioinformatics Date: 2013-01-16 Impact factor: 3.169
Authors: Pengfei Guo; Tristan Furnary; Vasilis Vasiliou; Qi Yan; Kate Nyhan; Dean P Jones; Caroline H Johnson; Zeyan Liew Journal: Environ Int Date: 2022-02-26 Impact factor: 9.621
Authors: Che-Jung Chang; Dana Boyd Barr; P Barry Ryan; Parinya Panuwet; Melissa M Smarr; Ken Liu; Kurunthachalam Kannan; Volha Yakimavets; Youran Tan; ViLinh Ly; Carmen J Marsit; Dean P Jones; Elizabeth J Corwin; Anne L Dunlop; Donghai Liang Journal: Environ Int Date: 2021-11-01 Impact factor: 9.621
Authors: Matthew C Hamilton; Melissa M Heintz; Marisa Pfohl; Emily Marques; Lucie Ford; Angela L Slitt; William S Baldwin Journal: Food Chem Toxicol Date: 2021-04-08 Impact factor: 5.572
Authors: Suzanne E Fenton; Alan Ducatman; Alan Boobis; Jamie C DeWitt; Christopher Lau; Carla Ng; James S Smith; Stephen M Roberts Journal: Environ Toxicol Chem Date: 2020-12-07 Impact factor: 4.218
Authors: Nikos Stratakis; David V Conti; Ran Jin; Katerina Margetaki; Damaskini Valvi; Alexandros P Siskos; Léa Maitre; Erika Garcia; Nerea Varo; Yinqi Zhao; Theano Roumeliotaki; Marina Vafeiadi; Jose Urquiza; Silvia Fernández-Barrés; Barbara Heude; Xavier Basagana; Maribel Casas; Serena Fossati; Regina Gražulevičienė; Sandra Andrušaitytė; Karan Uppal; Rosemary R C McEachan; Eleni Papadopoulou; Oliver Robinson; Line Småstuen Haug; John Wright; Miriam B Vos; Hector C Keun; Martine Vrijheid; Kiros T Berhane; Rob McConnell; Lida Chatzi Journal: Hepatology Date: 2020-10-19 Impact factor: 17.425